Point72 Asset Management’s X4 Pharmaceuticals XFOR Stock Holding History

Point72 Asset Management’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$192K	Buy	+41,072	New	+$169K	﹤0.01%	3555
2026 Q1	–	Sell	-808,154	Closed	-$3.23M	–	4605
2025 Q4	$3.23M	Buy	808,154 +786,488	+3,630%	+$2.86M	﹤0.01%	2151
2025 Q3	$74.1K	Sell	21,666 -1	-0%	-$3	﹤0.01%	2218
2025 Q2	$41.2K	Hold	21,667	–	–	﹤0.01%	2111
2025 Q1	$154K	Hold	21,667	–	–	﹤0.01%	1860
2024 Q4	$477K	Buy	21,667 +832	+4%	+$13.3K	﹤0.01%	1677
2024 Q3	$418K	Buy	20,835 +2,732	+15%	+$57K	﹤0.01%	1649
2024 Q2	$315K	Sell	18,103 -3,564	-16%	-$117K	﹤0.01%	1527
2024 Q1	$904K	Hold	21,667	–	–	﹤0.01%	1484
2023 Q4	$545K	Hold	21,667	–	–	﹤0.01%	1556
2023 Q3	$709K	Hold	21,667	–	–	﹤0.01%	1433
2023 Q2	$1.26M	Hold	21,667	–	–	﹤0.01%	1105
2023 Q1	$566K	Hold	21,667	–	–	﹤0.01%	1210
2022 Q4	$645K	Sell	21,667 -63,215	-74%	-$2.99M	﹤0.01%	1113
2022 Q3	$4.35M	Buy	84,882 +30,442	+56%	+$1.05M	0.02%	761
2022 Q2	$1.58M	Hold	54,440	–	–	0.01%	990
2022 Q1	$2.86M	Hold	54,440	–	–	0.01%	818
2021 Q4	$3.74M	Buy	+54,440	New	+$6.89M	0.01%	729

Other funds holding XFOR

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management's XFOR Position: Q2 2026 in Review

Point72 Asset Management opened a new position in X4 Pharmaceuticals (XFOR) in Q2 2026: 41,072 shares worth $192K. The stake represents ﹤0.01% of the portfolio and ranks #3555 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in XFOR as recently as Q4 2025.

Point72 Asset Management first reported a position in XFOR in Q4 2021 and has held it in 18 quarters since. The position peaked at $4.35M in Q3 2022. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

Point72 Asset Management held 41,072 shares of X4 Pharmaceuticals worth $192K as of Q2 2026.
X4 Pharmaceuticals was a new Point72 Asset Management position in Q2 2026.
X4 Pharmaceuticals made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #3555 holding.
Point72 Asset Management first reported a position in X4 Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
Point72 Asset Management's X4 Pharmaceuticals position peaked at $4.35M in Q3 2022.
89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.